Advanced search
Publication Cover
OncoTargets and Therapy Volume 15, 2022 - Issue
Submit an article Journal homepage
131
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Case Report: Targeted Therapy with Anlotinib for a Rare Case of Spinal Cord Glioblastoma with FGFR3 Mutation

Ruiqiong LiuCancer Center, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, People’s Republic of ChinaView further author information
,
Wei WeiCancer Center, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, People’s Republic of ChinaView further author information
,
Huaying HouCancer Center, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, People’s Republic of ChinaView further author information
,
Ping CongCancer Center, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, People’s Republic of ChinaView further author information
,
Yong ZhouCancer Center, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, People’s Republic of ChinaView further author information
&
Xiaoming YuCancer Center, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250033, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 771-776 | Published online: 11 Jul 2022

References

  • Cheng L, Yao Q, Ma L, et al. Predictors of mortality in patients with primary spinal cord glioblastoma. Eur Spine J. 2020;29(12):3203–3213. doi:10.1007/s00586-020-06515-3
  • Chanchotisatien A, Xiong J, Yu J, Chu S. Exophytic primary intramedullary spinal cord glioblastoma: case report and critical review of literature. World Neurosurg. 2019;122:573–576. doi:10.1016/j.wneu.2018.11.113
  • Adams H, Avendano J, Raza SM, Gokaslan ZL, Jallo GI, Quinones-Hinojosa A. Prognostic factors and survival in primary malignant astrocytomas of the spinal cord: a population-based analysis from 1973 to 2007. Spine. 2012;37(12):E727–E735. doi:10.1097/BRS.0b013e31824584c0
  • Ardizzone A, Scuderi SA, Giuffrida D, et al. Role of Fibroblast Growth Factors Receptors (FGFRs) in brain tumors, focus on astrocytoma and glioblastoma. Cancers. 2020;12(12):3825. doi:10.3390/cancers12123825
  • Dai S, Zhou Z, Chen Z, Xu G, Chen Y. Fibroblast Growth Factor Receptors (FGFRs): structures and small molecule inhibitors. Cells. 2019;8(6):614. doi:10.3390/cells8060614
  • Tiong KH, Mah LY, Leong CO. Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis. 2013;18(12):1447–1468. doi:10.1007/s10495-013-0886-7
  • Krook MA, Reeser JW, Ernst G, et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer. 2020;124(5):880–892. doi:10.1038/s41416-020-01157-0
  • Li J, Hu K, Huang J, Zhou L, Yan Y, Xu Z. Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment. Aging. 2021;13(12):16541–16566. doi:10.18632/aging.203175
  • Xie X, Lin J, Zhong Y, Fu M, Tang A. FGFR(3S249C) mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells. Exp Ther Med. 2019;18(2):1226–1234. doi:10.3892/etm.2019.7672
  • Wang Y, Liang D, Chen J, et al. Targeted therapy with anlotinib for a patient with an oncogenic FGFR3-TACC3 fusion and recurrent glioblastoma. Oncologist. 2020;26(3):173–177.
  • Wong AP, Dahdaleh NS, Fessler RG, et al. Risk factors and long-term survival in adult patients with primary malignant spinal cord astrocytomas. J Neurooncol. 2013;115(3):493–503. doi:10.1007/s11060-013-1251-y
  • Moinuddin FM, Alvi MA, Kerezoudis P, et al. Variation in management of spinal glioblastoma multiforme: results from a national cancer registry. J Neurooncol. 2019;141(2):441–447. doi:10.1007/s11060-018-03054-2
  • Weaver A, Bossaer JB. Fibroblast growth factor receptor (FGFR) inhibitors: a review of a novel therapeutic class. J Oncol Pharm Pract. 2020;27:1078155220983425.
  • Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22(1):259–267. doi:10.1158/1078-0432.CCR-14-3212
  • Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17(5):318–332. doi:10.1038/nrc.2017.8
  • Bernard-Pierrot I, Brams A, Dunois-Larde C, et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis. 2006;27(4):740–747. doi:10.1093/carcin/bgi290
  • Leroy B, Girard L, Hollestelle A, Minna JD, Gazdar AF, Soussi T. Analysis of TP53 mutation status in human cancer cell lines: a reassessment. Hum Mutat. 2014;35(6):756–765. doi:10.1002/humu.22556
  • Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105. doi:10.1186/s13045-016-0332-8
  • Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.3039

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.